Want to see JP:4571 full AI Analyst Report?
4571 Stock Chart & Stats
¥134.00
-¥1.00(-0.68%)
At close: 4:00 PM EST
¥134.00
-¥1.00(-0.68%)
Day’s Range― - ―
52-Week Range¥93.00 - ¥254.00
Previous CloseN/A
Volume236.30K
Average Volume (3M)2.35M
Market Cap
¥7.93B
Enterprise Value¥4.90B
Total Cash (Recent Filing)¥4.91B
Total Debt (Recent Filing)¥1.60B
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-12.91
Shares Outstanding83,536,760
10 Day Avg. Volume484,410
30 Day Avg. Volume2,345,523
Financial Highlights & Ratios
PEG Ratio-1.32
Price to Book (P/B)3.10
Price to Sales (P/S)63.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
High Gross Margins & Revenue ReboundA 50% revenue rebound and persistently high gross margins (72%–88%) indicate the core micelle delivery technology commands strong unit economics. Over a multi-month horizon this margin profile supports scalable gross-profit expansion as partnered programs progress and could allow incremental revenue to flow to improving operating leverage if SG&A growth is contained.
Collaboration/licensing Business ModelA model centered on collaborations, licensing, milestone payments and royalties reduces capital intensity versus full product commercialization. Structurally, this allows NanoCarrier to de-risk development by leveraging partner balance sheets, secure non-dilutive funding milestones, and scale revenue exposure to successful partner commercialization over time.
Moderate Leverage With Positive EquityDebt-to-equity below ~0.45 and persistent positive equity provide a buffer that lowers near-term insolvency risk and preserves access to capital markets. For a development-stage biotech, moderate leverage improves negotiating flexibility with partners and lenders and gives management runway to execute clinical and licensing milestones over the coming months.
Bears Say
Consistent Operating Cash BurnNegative operating cash flow each year shows the core business consumes cash rather than self-funds growth. Over a 2–6 month horizon this structural cash burn means the company remains reliant on external financing or milestone receipts, increasing funding risk and potential dilution if partner payments or financing windows do not materialize.
Persistent Net LossesMulti-year operating and net losses indicate the business has not yet converted its favorable gross margins into positive operating profitability. Structurally, continued negative margins erode equity value, constrain reinvestment capacity, and require sustained partner support or financing to reach break-even, raising long-term shareholder risk.
Rising Debt And Shrinking Assets/equityA material increase in debt to 1.6B alongside declining assets and equity reduces financial flexibility and raises leverage-related constraints. Over months this trend heightens refinancing and covenant risk, may increase interest expense, and can weaken the company’s bargaining position in licensing talks or capital raises, potentially forcing unfavorable terms.
NanoCarrier Co., Ltd. News
4571 FAQ
What was NanoCarrier Co., Ltd.’s price range in the past 12 months?
NanoCarrier Co., Ltd. lowest stock price was ¥93.00 and its highest was ¥254.00 in the past 12 months.
What is NanoCarrier Co., Ltd.’s market cap?
NanoCarrier Co., Ltd.’s market cap is ¥7.93B.
When is NanoCarrier Co., Ltd.’s upcoming earnings report date?
NanoCarrier Co., Ltd.’s upcoming earnings report date is Aug 07, 2026 which is in 7 days.
How were NanoCarrier Co., Ltd.’s earnings last quarter?
NanoCarrier Co., Ltd. released its earnings results on May 15, 2026. The company reported -¥3.84 earnings per share for the quarter, missing the consensus estimate of N/A by -¥3.84.
Is NanoCarrier Co., Ltd. overvalued?
According to Wall Street analysts NanoCarrier Co., Ltd.’s price is currently Overvalued.
Does NanoCarrier Co., Ltd. pay dividends?
NanoCarrier Co., Ltd. does not currently pay dividends.
What is NanoCarrier Co., Ltd.’s EPS estimate?
NanoCarrier Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NanoCarrier Co., Ltd. have?
NanoCarrier Co., Ltd. has 83,536,760 shares outstanding.
What happened to NanoCarrier Co., Ltd.’s price movement after its last earnings report?
NanoCarrier Co., Ltd. reported an EPS of -¥3.84 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.899%.
Which hedge fund is a major shareholder of NanoCarrier Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4571
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NanoCarrier Co., Ltd.
NANO MRNA Co., Ltd. specializes in the discovery, advancement, and manufacturing of pharmaceutical products, employing its innovative micellar nanoparticle platform. Its biopharmaceutical pipeline is primarily geared towards addressing oncological conditions and a range of other severe illnesses. The enterprise also undertakes the full spectrum of activities for anti-cancer medications, from initial scientific investigation to market commercialization, all underpinned by its distinctive micellar nanoparticle approach. Established on June 14, 1996, by Kazunori Kataoka, Teruo Okano, and Ichiro Nakatomi, the firm maintains its principal operations in Tokyo, Japan.
Technical Analysis
AnGes
―
OncoTherapy Science
―
Chiome Bioscience Inc.
―
Oncolys BioPharma, Inc.
―
STELLA PHARMA CORPORATION
―